CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: KCNMB3 (ImmuneEditome ID:27094)

1. Gene summary of enriched editing regions for KCNMB3

check button Gene summary
Gene informationGene symbol

KCNMB3

Gene ID

27094

GeneSynonymsBKBETA3|HBETA3|K(VCA)BETA-3|KCNMB2|KCNMBL|SLO-BETA-3|SLOBETA3
GeneCytomap

3q26.32

GeneTypeprotein-coding
GeneDescriptioncalcium-activated potassium channel subunit beta-3|BK channel beta subunit 3|BK channel subunit beta-3|MaxiK channel beta-subunit 3|big potassium channel beta subunit 3|calcium-activated potassium channel regulatory subunit|calcium-activated potassium channel, subfamily M subunit beta-3|charybdotoxin receptor subunit beta-3|large conductance, voltage and Ca2+ activated potassium channel Maxi K beta 3 subunit|maxi K channel subunit beta-3|potassium channel subfamily M regulatory beta subunit 3|potassium large conductance calcium-activated channel, subfamily M beta member 3
GeneModificationdate20230329
UniprotIDQ9NPA1;A0A087WV41
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr3:179251741-179255119:-ENST00000349697.2ENSG00000171121.15KCNMB3intronicAluSc5,L1MEd,AluSx,MER102b,AluSx1,AluYchr3:179251741-179255119:-.alignment
chr3:179251741-179255119:-ENST00000392686.5ENSG00000171121.15KCNMB3intronicAluSc5,L1MEd,AluSx,MER102b,AluSx1,AluYchr3:179251741-179255119:-.alignment
chr3:179251741-179255119:-ENST00000485523.4ENSG00000171121.15KCNMB3intronicAluSc5,L1MEd,AluSx,MER102b,AluSx1,AluYchr3:179251741-179255119:-.alignment
chr3:179251741-179255119:-ENST00000497599.4ENSG00000171121.15KCNMB3intronicAluSc5,L1MEd,AluSx,MER102b,AluSx1,AluYchr3:179251741-179255119:-.alignment
chr3:179256265-179258066:-ENST00000349697.2ENSG00000171121.15KCNMB3intronicL1MEd,AluJo,AluSx,AluJr,AluSq2,(TG)nchr3:179256265-179258066:-.alignment
chr3:179256265-179258066:-ENST00000392686.5ENSG00000171121.15KCNMB3intronicL1MEd,AluJo,AluSx,AluJr,AluSq2,(TG)nchr3:179256265-179258066:-.alignment
chr3:179256265-179258066:-ENST00000485523.4ENSG00000171121.15KCNMB3intronicL1MEd,AluJo,AluSx,AluJr,AluSq2,(TG)nchr3:179256265-179258066:-.alignment
chr3:179256265-179258066:-ENST00000497599.4ENSG00000171121.15KCNMB3intronicL1MEd,AluJo,AluSx,AluJr,AluSq2,(TG)nchr3:179256265-179258066:-.alignment


Top

2. Tumor-specific enriched editing regions for KCNMB3


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr3:179256265-179258066:-BRCAPathEER2.3955e-022.9314e-020.3586image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for KCNMB3


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for KCNMB3


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

5. Enriched editing regions and immune infiltration for KCNMB3


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr3:179251741-179255119:-BRCAEERMacrophages_M11.1696e-03-0.4546image
chr3:179256265-179258066:-BRCAEERDendritic_cells_resting1.2891e-02-0.4050image
ENSG00000171121.15,KCNMB3BRCAEAGT_cells_regulatory_(Tregs)3.8750e-02-0.2476image
chr3:179251741-179255119:-ESCAEERDendritic_cells_resting3.1691e-020.3997image
chr3:179256265-179258066:-ESCAEERMacrophages_M01.4041e-03-0.6506image
ENSG00000171121.15,KCNMB3ESCAEAGMacrophages_M05.8795e-03-0.4501image
ENSG00000171121.15,KCNMB3LUSCEAGB_cells_naive1.5727e-02-0.4444image
chr3:179251741-179255119:-STADEERNK_cells_resting3.9479e-020.3548image
chr3:179256265-179258066:-STADEERT_cells_CD85.2031e-030.5741image


Top

6. Enriched editing regions and immune gene sets for KCNMB3


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr3:179251741-179255119:-BRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.0406e-03-0.4343image
ENSG00000171121.15,KCNMB3BRCAGSVA_HALLMARK_UV_RESPONSE_DNEAG1.3051e-020.2954image
chr3:179256265-179258066:-BRCAGSVA_HALLMARK_ANDROGEN_RESPONSEEER2.5443e-030.4816image
chr3:179256265-179258066:-ESCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.8237e-020.4784image
chr3:179251741-179255119:-ESCAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.0457e-020.4680image
ENSG00000171121.15,KCNMB3ESCAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG3.3501e-02-0.3552image
ENSG00000171121.15,KCNMB3LUSCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.3179e-020.4204image
chr3:179256265-179258066:-STADGSVA_HALLMARK_G2M_CHECKPOINTEER9.2243e-03-0.5416image
chr3:179251741-179255119:-STADGSVA_HALLMARK_SPERMATOGENESISEER5.6183e-03-0.4648image
ENSG00000171121.15,KCNMB3STADGSVA_HALLMARK_SPERMATOGENESISEAG8.6630e-03-0.4001image


Top

7. Enriched editing regions and drugs for KCNMB3


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr3:179251741-179255119:-BRCACCT007093EER1.1436e-04-0.5281image
ENSG00000171121.15,KCNMB3BRCAAKT.inhibitor.VIIIEAG1.4997e-02-0.2897image
chr3:179256265-179258066:-ESCABMS.708163EER2.7875e-03-0.6187image
chr3:179251741-179255119:-ESCACCT007093EER6.7396e-03-0.4918image
ENSG00000171121.15,KCNMB3ESCAKU.55933EAG1.3104e-02-0.4096image
ENSG00000171121.15,KCNMB3LUSCCyclopamineEAG2.2761e-02-0.4215image
ENSG00000171121.15,KCNMB3OVJNJ.26854165EAG1.0939e-02-0.5313image
chr3:179256265-179258066:-STADCyclopamineEER2.0536e-02-0.4903image
chr3:179251741-179255119:-STADJNK.9LEER8.0426e-030.4470image
ENSG00000171121.15,KCNMB3STADAICAREAG2.6990e-030.4513image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType
chr3:179251741-179255119:-ENST00000349697.2Q9NPA1DB00721ProcaineSmallMoleculeDrug
chr3:179251741-179255119:-ENST00000349697.2Q9NPA1DB00867RitodrineSmallMoleculeDrug
chr3:179251741-179255119:-ENST00000349697.2Q9NPA1DB01054NitrendipineSmallMoleculeDrug
chr3:179251741-179255119:-ENST00000349697.2Q9NPA1DB01110MiconazoleSmallMoleculeDrug
chr3:179251741-179255119:-ENST00000349697.2Q9NPA1DB09089TrimebutineSmallMoleculeDrug
chr3:179251741-179255119:-ENST00000392686.5Q9NPA1DB00721ProcaineSmallMoleculeDrug
chr3:179251741-179255119:-ENST00000392686.5Q9NPA1DB00867RitodrineSmallMoleculeDrug
chr3:179251741-179255119:-ENST00000392686.5Q9NPA1DB01054NitrendipineSmallMoleculeDrug
chr3:179251741-179255119:-ENST00000392686.5Q9NPA1DB01110MiconazoleSmallMoleculeDrug
chr3:179251741-179255119:-ENST00000392686.5Q9NPA1DB09089TrimebutineSmallMoleculeDrug
chr3:179251741-179255119:-ENST00000485523.4Q9NPA1DB00721ProcaineSmallMoleculeDrug
chr3:179251741-179255119:-ENST00000485523.4Q9NPA1DB00867RitodrineSmallMoleculeDrug
chr3:179251741-179255119:-ENST00000485523.4Q9NPA1DB01054NitrendipineSmallMoleculeDrug
chr3:179251741-179255119:-ENST00000485523.4Q9NPA1DB01110MiconazoleSmallMoleculeDrug
chr3:179251741-179255119:-ENST00000485523.4Q9NPA1DB09089TrimebutineSmallMoleculeDrug
chr3:179251741-179255119:-ENST00000497599.4Q9NPA1DB00721ProcaineSmallMoleculeDrug
chr3:179251741-179255119:-ENST00000497599.4Q9NPA1DB00867RitodrineSmallMoleculeDrug
chr3:179251741-179255119:-ENST00000497599.4Q9NPA1DB01054NitrendipineSmallMoleculeDrug
chr3:179251741-179255119:-ENST00000497599.4Q9NPA1DB01110MiconazoleSmallMoleculeDrug
chr3:179251741-179255119:-ENST00000497599.4Q9NPA1DB09089TrimebutineSmallMoleculeDrug
chr3:179256265-179258066:-ENST00000349697.2Q9NPA1DB00721ProcaineSmallMoleculeDrug
chr3:179256265-179258066:-ENST00000349697.2Q9NPA1DB00867RitodrineSmallMoleculeDrug
chr3:179256265-179258066:-ENST00000349697.2Q9NPA1DB01054NitrendipineSmallMoleculeDrug
chr3:179256265-179258066:-ENST00000349697.2Q9NPA1DB01110MiconazoleSmallMoleculeDrug
chr3:179256265-179258066:-ENST00000349697.2Q9NPA1DB09089TrimebutineSmallMoleculeDrug
chr3:179256265-179258066:-ENST00000392686.5Q9NPA1DB00721ProcaineSmallMoleculeDrug
chr3:179256265-179258066:-ENST00000392686.5Q9NPA1DB00867RitodrineSmallMoleculeDrug
chr3:179256265-179258066:-ENST00000392686.5Q9NPA1DB01054NitrendipineSmallMoleculeDrug
chr3:179256265-179258066:-ENST00000392686.5Q9NPA1DB01110MiconazoleSmallMoleculeDrug
chr3:179256265-179258066:-ENST00000392686.5Q9NPA1DB09089TrimebutineSmallMoleculeDrug
chr3:179256265-179258066:-ENST00000485523.4Q9NPA1DB00721ProcaineSmallMoleculeDrug
chr3:179256265-179258066:-ENST00000485523.4Q9NPA1DB00867RitodrineSmallMoleculeDrug
chr3:179256265-179258066:-ENST00000485523.4Q9NPA1DB01054NitrendipineSmallMoleculeDrug
chr3:179256265-179258066:-ENST00000485523.4Q9NPA1DB01110MiconazoleSmallMoleculeDrug
chr3:179256265-179258066:-ENST00000485523.4Q9NPA1DB09089TrimebutineSmallMoleculeDrug
chr3:179256265-179258066:-ENST00000497599.4Q9NPA1DB00721ProcaineSmallMoleculeDrug
chr3:179256265-179258066:-ENST00000497599.4Q9NPA1DB00867RitodrineSmallMoleculeDrug
chr3:179256265-179258066:-ENST00000497599.4Q9NPA1DB01054NitrendipineSmallMoleculeDrug
chr3:179256265-179258066:-ENST00000497599.4Q9NPA1DB01110MiconazoleSmallMoleculeDrug
chr3:179256265-179258066:-ENST00000497599.4Q9NPA1DB09089TrimebutineSmallMoleculeDrug